-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – June 23, 2026 14:00 ET | Source: Coherus Oncology, Inc. REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech…
-
Texas A&M Study Highlights Pictor PictVet® as a Promising New Tool for Non-Invasive Beef Cattle Health Monitoring
Independent peer-reviewed research published in Frontiers in Veterinary Science reports strong assay performance in a proof-of-concept evaluation using bovine nasopharyngeal swab samples CARLSBAD, Calif., June 22, 2026 /PRNewswire/ — Pictor Holdings Inc., a global targeted proteomic platform company, today highlighted the publication of an independent peer-reviewed study conducted by researchers at Texas A&M University and published…
-
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal Immunotherapy (OMIT)
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the Oral Mucosal Escalation Goal Assessment (OMEGA) Phase 1 safety trial at the 2026 Eastern Allergy…
-
THE POWER OF PLAY: NEW RESEARCH CONFIRMS JUST SECONDS OF PLAY INSTANTLY BRING FAMILIES CLOSER
Findings from Phase 2 of the “Power of Play: Family Connection” study from Kinder and the University of East London (UEL) confirm that shared play is a powerful catalyst for strengthening emotional and physical connection between parents and children. To further support families and kids in playtime, Kinder has expanded its Value of Play hub…
-
The Truth About Global Brands
Truth Is Everything: 72% of People Say It’s More Important than Ever to Prioritize Truth Research from McCann and Economist Enterprise reveals global growth will be driven by brands’ ability to eliminate doubt and connect with the world’s fastest-growing audience with ideas that move at the speed and flow of culture NEW YORK, June 11, 2026 /PRNewswire/ — McCann today released The Truth About Global Brands, a study of 20,713 people across…
-
Published Study Shows Clinically Significant Energy, Performance, and Metabolic Benefits of FutureCeuticals’ Caffinity™
MOMENCE, Ill., June 10, 2026 /PRNewswire/ — FutureCeuticals, Inc. is pleased to announce the peer-reviewed publication of clinical research demonstrating unique energy, performance, and metabolic benefits of Caffinity™, a proprietary ingredient derived from the Arabica coffee cherry (bean and fruit). This study, conducted by recognized experts in energy metabolism at the University of Exeter (UK), establishes…
-
IAMAI and WTW India Release India's First Compensation Benchmarking Study for Technology Sector
Bengaluru, Karnataka, India The Internet and Mobile Association of India (IAMAI) and WTW India have partnered to produce the WTW India & IAMAI Comprehensive Compensation Benchmarking Study for Technology Sector, the first comprehensive report in the country to examine compensation data for unique job roles. The benchmarking study addresses the growing need for standardized compensation…
-
NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials
Kwun Tong, Kowloon, HK, June 05, 2026 (GLOBE NEWSWIRE) — The newly registered 56-day exploratory study of NatureU® Mind Care BeautyU Caps — reporting within-participant changes of −46.7% in crow’s-feet wrinkle count and +58.7% in stratum corneum hydration at Day 56 — joins NatureU’s prior sleep and satiety clinical trials, both already published in peer-reviewed…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
